Takeda Pharmaceutical Co (Takeda), a Japanese multinational pharmaceutical and biopharmaceutical company, has said it would import and distribute 50 million doses of Moderna Inc's COVID-19 vaccine candidate in Japan, Reuter news agency reported on Thursday.
Under this deal, Takeda will be responsible for securing regulatory approval for the vaccine, known as mRNA-1273, with supply starting in the first half of 2021, Takeda said in a release.
Reportedly, the companies were previously in talks to supply 40 million or more doses of the vaccine in Japan.
Moderna's candidate is in late-stage trials in the US.
Also, Takeda has agreed to produce Novavax Inc's COVID-19 vaccine, aiming to make 250 million doses for use in Japan.
Pfizer reports positive Phase 3 data for ABRYSVO in adults at risk for RSV disease
Clover Bio announces SCB-1019 vaccine candidate Phase I trial data in initial young adult cohort
Sanofi launches Verorab for rabies prophylaxis in UK
BioVaxys expands patent portfolio for DPX delivery platform and advances DPX SurMAGE
YS Biopharma repays USD40m loan facility
Kintara Therapeutics and TuHURA Biosciences to merge
VGXI names new chief accounting officer
Moderna reports positive interim results from next-generation COVID-19 vaccine trial
Valneva launches Phase 1 trial for next-generation Zika vaccine
Circio Holding ASA confirms licensing deal with IOVaxis Therapeutics in China and Singapore
Everest Medicines names new chief medical officer and chief product officer
Pfizer's PREVENAR 20 gains European Commission approval for paediatric pneumococcal vaccine